All In Biotech

Drug Trial Radar · NCT04970901

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

Last checked: Nov 20, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

154

Actual

Start

Jun 17, 2022

Primary completion

Mar 31, 2027

Study completion Apr 30, 2028

Sponsor

Lead sponsor
ADC Therapeutics S.A.Industry
Sponsor type
Industry
First posted
Jul 21, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) for the combinations.

Conditions

  • B-Cell Non-Hodgkin Lymphoma
  • Relapsed B-Cell Non-Hodgkin Lymphoma
  • Refractory B-Cell Non-Hodgkin Lymphoma

Interventions

  • Loncastuximab TesirineDrug

    Intravenous (IV) infusion

  • Polatuzumab VedotinDrug

    IV infusion

  • GlofitamabDrug

    IV infusion

  • MosunetuzumabDrug

    Subcutaneous (SC) injection

  • ObinutuzumabDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)Time frame: Day 1 to Day 21 of Cycle 1, where a cycle is 21 days
  2. Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)Time frame: Up to approximately 2 years for Arm C and 3 years for Arms E and F
  3. Number of Participants Who Experience an Adverse Event (AE) Leading to Dose DelayTime frame: Up to approximately 1 year
  4. Number of Participants Who Experience an Adverse Event (AE) Leading to Dose InterruptionTime frame: Up to approximately 1 year
  5. Number of Participants Who Experience an Adverse Event (AE) Leading to Dose ReductionTime frame: Up to approximately 1 year
  6. Number of Participants Who Experience a Clinically Significant Change from Baseline in Safety Laboratory MeasurementsTime frame: Baseline up to approximately 1 year
  7. Number of Participants Who Experience a Clinically Significant Change from Baseline in Vital SignsTime frame: Baseline up to approximately 1 year
  8. Number of Participants Who Experience a Clinically Significant Change from Baseline in Eastern Cooperative Oncology Group (ECOG) Performance StatusTime frame: Baseline up to approximately 1 year
  9. Number of Participants Who Experience a Clinically Significant Change from Baseline in 12-Lead Electrocardiogram (ECG) MeasurementsTime frame: Baseline up to approximately 1 year

Locations

40 sites in 6 countries. Site status is shown where the registry gives one.

  • University of California San Francisco - Fresno Center for Medical Education and Research

    Clovis, California

  • Scripps Health - Prebys Cancer Center

    San Diego, California

  • Sylvester Comprehensive Cancer Center

    Miami, Florida

  • Miami Cancer Institute

    Miami, Florida

  • Memorial Cancer Institute - Memorial Hospital West

    Pembroke Pines, Florida

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia

  • The Blood and Marrow Transplant Group of Georgia

    Atlanta, Georgia

  • Mission Cancer + Blood - Mission Cancer Foundation

    Des Moines, Iowa

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • University of Minnesota

    Minneapolis, Minnesota

  • Columbia University Irving Medical Center

    New York, New York

  • Cleveland Clinic Main Campus

    Cleveland, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • Penn Medicine - Perelman Center for Advanced Medicine

    Philadelphia, Pennsylvania

  • Allegheny Health Network - West Penn Hospital

    Pittsburgh, Pennsylvania

  • Brown University Health - Rhode Island Hospital

    Providence, Rhode Island

  • Hollings Cancer Center

    Charleston, South Carolina

  • Greco-Hainsworth Tennessee Oncology Centers for Research (GHCR)

    Nashville, Tennessee

  • Baylor University Medical Center

    Dallas, Texas

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • Emily Couric Clinical Cancer Center

    Charlottesville, Virginia

  • NEXT Virginia (Virginia Cancer Specialists)

    Fairfax, Virginia

  • Froedtert & Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • Centre Hospitalier Universitaire Universite Catholique de Louvain - Site Godinne

    Yvoir, Belgium

  • Fakultni nemocnice Ostrava

    Ostrava, Czechia

  • Fakultní Nemocnice Královské Vinohrady

    Prague, Czechia

  • Fakultni nemocnice v Motole

    Prague, Czechia

  • Azienda Socio Sanitaria Territoriale (ASST) Papa Giovanni XXIII

    Bergamo, Italy

  • Centro di Ricerche Cliniche - IRCCS Azienda Ospedaliero Universitaria di Bologna

    Bologna, Italy

  • Azienda Socio Sanitaria Territoriale (ASST) degli Spedali Civili di Brescia

    Brescia, Italy

  • Istituto Europeo di Oncologia

    Milan, Italy

  • Institut Català d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet)

    Barcelona, Spain

  • Hospital General Universitario Gregorio Marañón

    Madrid, Spain

  • Hospital Universitario Ramón y Cajal

    Madrid, Spain

  • Complejo Asistencial Universitario de Salamanca - Hospital Clínico

    Salamanca, Spain

  • Hospital Universitari i Politècnic La Fe

    Valencia, Spain

  • University College London Hospitals NHS Foundation Trust

    London, United Kingdom

  • Oxford University Hospitals NHS Foundation Trust

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.